New hope for kids with tough brain cancers: experimental drug trial launches
NCT ID NCT07331064
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests an experimental drug called gallium maltolate in 15 children whose high-grade glioma or atypical teratoid rhabdoid tumor has returned or not responded to treatment. The main goals are to find safe doses and understand side effects. Everyone receives the drug, and researchers hope this leads to better future treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL TERATOID RHABDOID TUMORS (ATRT) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a parasite drug fight childhood brain tumors?
- Could an antiparasitic drug boost radiation against childhood brain tumors?
- Could Pre-Surgery proton beams boost brain tumor outcomes?
- New drug cocktail aims to outsmart childhood brain tumors
- Engineered immune cells target deadly brain tumors in children
- Oxygen-Enhanced MRI could sharpen radiotherapy for deadly brain cancers